Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):456–460. doi: 10.1038/bjc.1992.92

Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.

P R Maddox 1, D L Jones 1, R E Mansel 1
PMCID: PMC1977614  PMID: 1558804

Abstract

Basal prolactin (PRL) and total lactogenic hormone (TLH) levels were measured using a new microbioassay (BA) and conventional immunoradiometric assay (IRMA) in patients with breast cancer and compared to an age-matched control group. No significant differences were found using the IRMA, but BA lactogenic levels were significantly elevated in breast cancer patients compared controls, leading to a markedly elevated BA/IRMA ratio for both PRL (2.7 vs 1.4, P less than 0.0001) and TLH (2.8 vs 1.4, P less than 0.0001) which was greatest for postmenopausal women. Using the mean +2 standard deviations as the upper limit of normal, there was no significant difference between breast cancer patients and controls for IRMA, but BA and BA/IRMA PRL levels were elevated in 42% and 61% of the patients, respectively. There was a weak negative correlation of BA and IRMA PRL with age for normals (r = -0.53 for both) but no correlation was evident for breast cancer patients (r = 0.06 and -0.13, respectively) implying a sustained absolute and relative bioactive hyperprolactinaemia at all ages. These results show increased lactogenic bioactivity in breast cancer and suggest that different forms of bioactive prolactin undetected by IRMA (or enhancing serum factors) are present in the sera of these patients.

Full text

PDF
456

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldinger K. A., Schultz P. N., Blumenschein G. R., Samaan N. A. Thyroid-stimulating hormone and prolactin levels in breast cancer. Arch Intern Med. 1978 Nov;138(11):1638–1641. [PubMed] [Google Scholar]
  2. Anderson E., Morten H., Wang D. Y., Burns P., Birch J., Howell A. Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1719–1725. doi: 10.1016/0277-5379(89)90340-4. [DOI] [PubMed] [Google Scholar]
  3. Barni S., Lissoni P., Tancini G., Crispino S., Paolorossi F., Rovelli F., Fumagalli G., Ferri L. Prolactin response to thyrotropin-releasing hormone in early and advanced human breast cancer. Tumori. 1986 Aug 31;72(4):399–403. doi: 10.1177/030089168607200410. [DOI] [PubMed] [Google Scholar]
  4. Farkouh N. H., Packer M. G., Frantz A. G. Large molecular size prolactin with reduced receptor activity in human serum: high proportion in basal state and reduction after thyrotropin-releasing hormone. J Clin Endocrinol Metab. 1979 Jun;48(6):1026–1032. doi: 10.1210/jcem-48-6-1026. [DOI] [PubMed] [Google Scholar]
  5. Franks S., Ralphs D. N., Seagroatt V., Jacobs H. S. Prolactin concentrations in patients with breast cancer. Br Med J. 1974 Nov 9;4(5940):320–321. doi: 10.1136/bmj.4.5940.320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Garnier P. E., Aubert M. L., Kaplan S. L., Grumbach M. M. Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of "Big" prolactin in a radioreceptor assay and evidence for its secretion. J Clin Endocrinol Metab. 1978 Dec;47(6):1273–1281. doi: 10.1210/jcem-47-6-1273. [DOI] [PubMed] [Google Scholar]
  7. Jones M. K., Ramsay I. D., Collins W. P., Dyer G. I. The relationship of plasma prolactin to 17-B oestradiol in women with tumours of the breast. Eur J Cancer. 1977 Oct;13(10):1109–1112. doi: 10.1016/0014-2964(77)90008-1. [DOI] [PubMed] [Google Scholar]
  8. Kwa H. G., De Jong-Bakker M., Engelsman E., Cleton F. J. Plasma-prolactin in human breast cancer. Lancet. 1974 Mar 16;1(7855):433–435. doi: 10.1016/s0140-6736(74)92385-x. [DOI] [PubMed] [Google Scholar]
  9. Maddox P. R., Jones D. L., Mansel R. E. A new microbioassay for the measurement of lactogenic hormones in human serum. Horm Res. 1989;32(5-6):218–223. doi: 10.1159/000181293. [DOI] [PubMed] [Google Scholar]
  10. Ohgo S., Kato Y., Chihara K., Imura H. Plasma prolactin responses to thyrotropin-releasing hormone in patients with breast cancer. Cancer. 1976 Mar;37(3):1412–1416. doi: 10.1002/1097-0142(197603)37:3<1412::aid-cncr2820370323>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  11. Rose D. P., Pruitt B. T. Plasma prolactin levels in patients with breast cancer. Cancer. 1981 Dec 15;48(12):2687–2691. doi: 10.1002/1097-0142(19811215)48:12<2687::aid-cncr2820481221>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  12. Secreto G., Recchione C., Cavalleri A., Miraglia M., Dati V. Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer. 1983 Feb;47(2):269–275. doi: 10.1038/bjc.1983.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sheth N. A., Ranadive K. J., Suraiya J. N., Sheth A. R. Circulating levels of prolactin in human breast cancer. Br J Cancer. 1975 Aug;32(2):160–167. doi: 10.1038/bjc.1975.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sinha Y. N., Selby F. W., Lewis U. J., VanderLaan W. P. A homologous radioimmunoassay for human prolactin. J Clin Endocrinol Metab. 1973 Mar;36(3):509–516. doi: 10.1210/jcem-36-3-509. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES